Evidence map›Paper›PMID 41767112›Full record

ArticleTobacco induced diseases2026

Global burden of tobacco-induced atrial fibrillation/flutter: Trends from 1990 to 2021 and projections to 2045 based on the Global Burden of Disease study.

Lei Chen, Zhiqiang Zhang, Litao Wang, Ruimin Pan, Jing Yang, Weihong Lin, Jilang Zeng, Cheng Yu, Lianglong Chen

Abstract read
In one paragraph

Article in Tobacco induced diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lei Chen *Department of Cardiology, Fujian Medical University Union Hospital, Fujian Cardiovascular Medicine Center, Fujian Institute of Coronary Artery Disease, Fujian Cardiovascular Research Center, Fujian Medical University Heart Center, Fuzhou, China.
Zhiqiang Zhang *Department of Cardiology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.
Litao Wang *Department of Cardiology, Fujian Medical University Union Hospital, Fujian Cardiovascular Medicine Center, Fujian Institute of Coronary Artery Disease, Fujian Cardiovascular Research Center, Fujian Medical University Heart Center, Fuzhou, China.
Ruimin PanDepartment of Cardiology, Fujian Medical University Union Hospital, Fujian Cardiovascular Medicine Center, Fujian Institute of Coronary Artery Disease, Fujian Cardiovascular Research Center, Fujian Medical University Heart Center, Fuzhou, China.
Jing YangDepartment of Cardiology, Fujian Medical University Union Hospital, Fujian Cardiovascular Medicine Center, Fujian Institute of Coronary Artery Disease, Fujian Cardiovascular Research Center, Fujian Medical University Heart Center, Fuzhou, China.
Weihong LinDepartment of Cardiology, Fujian Medical University Union Hospital, Fujian Cardiovascular Medicine Center, Fujian Institute of Coronary Artery Disease, Fujian Cardiovascular Research Center, Fujian Medical University Heart Center, Fuzhou, China.
Jilang ZengDepartment of Cardiology, Fujian Medical University Union Hospital, Fujian Cardiovascular Medicine Center, Fujian Institute of Coronary Artery Disease, Fujian Cardiovascular Research Center, Fujian Medical University Heart Center, Fuzhou, China.
Cheng YuDepartment of Cardiology, Fujian Medical University Union Hospital, Fujian Cardiovascular Medicine Center, Fujian Institute of Coronary Artery Disease, Fujian Cardiovascular Research Center, Fujian Medical University Heart Center, Fuzhou, China.
Lianglong ChenDepartment of Cardiology, Fujian Medical University Union Hospital, Fujian Cardiovascular Medicine Center, Fujian Institute of Coronary Artery Disease, Fujian Cardiovascular Research Center, Fujian Medical University Heart Center, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTobacco use is a key modifiable risk factor for atrial fibrillation/flutter (AF/AFL). We assessed global, regional, and national burdens attributable to smoking from 1990 to 2021 and projected future trends.

methodsData on deaths and DALYs were extracted from the GBD 2021 study. Main statistical analyses included the calculation of ASMR and ASDR. Trends were quantified using the estimated annual percentage change (EAPC). An age-period-cohort (APC) model was employed to decompose the effects of age, period, and birth cohort. Furthermore, a Bayesian age-period-cohort (BAPC) model was utilized to project the disease burden through 2045.

resultsIn 2021, AF/AFL related to tobacco caused around 396000 cases, more than 10000 deaths, and 400000 disability-adjusted life years (DALYs). Compared with 1990, absolute cases and DALYs increased, while ASDR and ASR DALY declined (20%). High SDI regions improved most; low SDI regions lagged. Men and older adults bore disproportionate burdens. By 2045, deaths are projected to reach 14500 and 4200, respectively. Despite rising absolute DALYs, ASMR and ASDR are expected to decline in both sexes.

conclusionsAlthough standardized rates declined, the absolute burden of tobacco-related AF/AFL continues to rise, highlighting the urgent need for stronger tobacco control and targeted interventions in vulnerable populations.

Indexed as

atrial fibrillation/flutterDALYsGlobal Burdensociodemographic index (SDI)tobacco

Identifiers

PMID41767112
PMCPMC12937991

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.